• Save €2.00

VIVIN C * 20CPR EFF 330MG + 200MG

  • 020096020

Indicated in case of colds and febrile states.

Indicated in case of joint and muscle pain.

Deductible over-the-counter drug.

Anti-inflammatory, analgesic and antioxidant action.

info_outline View product sheet
Final Price €7.30
Regular Price €9.30
Save €2.00
check_circle Available (11 Items)
  Convenient and safe payments

Even with a credit card

  Shipping in 48h-72h all over the world

FREE in Italy over € 39.90

  Fast returns and 14 days to reconsider

14 days to reconsider

  90 years of pharmaceutical experience at your service

Always at your service

Drugs Others products at unbeatable price


Discover all products

VIVIN C * 20CPR EFF 330MG + 200MG

Therapeutic indications

Headache and toothache, neuralgia, menstrual pain, rheumatic and muscle pain. Symptomatic therapy of febrile states and flu and cold syndromes.

Dosage and method of use

Adults: 1-2 tablets if necessary up to 3-4 times a day. Dissolve one or two VIVIN C tablets in half a glass of non-carbonated water. The product should be taken on a full stomach. Do not exceed the recommended doses: in particular elderly patients should follow the minimum dosages indicated above.


Hypersensitivity to the active ingredients, to salicylates or to any of the excipients, an established tendency to bleeding, gastropathies (eg gastro-duodenal ulcer), asthma. History of gastrointestinal haemorrhage or perforation related to previous active treatments or history of recurrent peptic haemorrhage / ulcer (two or more distinct episodes of proven ulceration or bleeding). Severe heart failure. The use of this medicine is contraindicated in children and young people under the age of 16. Dose> 100 mg / day during the third trimester of pregnancy

Side effects

Gastrointestinal disorders : The most commonly observed adverse events are gastrointestinal in nature. Following administration of VIVIN C, the following have been reported: - nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4). - peptic ulcer, even perforated - Gastrointestinal haemorrhage, which can be manifest (haematemesis, melaena) and sometimes fatal, or occult and cause iron deficiency anemia. Such bleeding is more frequent with increasing dosage, particularly in elderly patients (see section 4.4). - Gastritis was observed less frequently. Cardiac pathologies: - Edema, hypertension and heart failure have been reported in association with NSAID treatment. Skin and subcutaneous tissue disorders : - Bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Disorders of the blood and lymphatic system: - Hemorrhagic syndromes (epistaxis, gingival hemorrhages, thrombocytopenia, purpura) with increased bleeding time. This effect persists for 4-8 days after stopping the administration of acetylsalicylic acid. It causes bleeding risk in patients undergoing surgery. - High doses of vitamin C (> 1g) may increase hemolysis in patients with G6PD dehydrogenase deficiency in the form of chronic hemolysis Disorders of the immune system: - Hypersensitivity reactions: angioedema, Quincke's edema, urticaria, erythema, asthma, anaphylactic reactions. Nervous system disorders: - Ear buzz; - Feeling of hearing loss; - Headache, usually a sign of overdose. Pregnancy, puerperium and perinatal conditions : - Delayed childbirth. Renal and urinary disorders: - High doses of vitamin C (> 1g) can promote the formation of oxalate and uric acid stones in some individuals.

Special warnings

This medicinal product should not be used in children and young people under the age of 16 (see section 4.3). Cases of Reye's syndrome have been observed in children with viral infections (particularly chicken pox and flu-like conditions) and treated with acetylsalicylic acid. Reye's syndrome is manifested by persistent vomiting and signs of progressive damage to the central nervous system (numbness, leading to generalized seizures and coma), signs of liver injury and hypoglycemia. People over 70 years of age, especially in the presence of concomitant therapies, should only use this medicine after consulting a doctor. After three days of use at the maximum dose or after 5-7 days of continuous use, consult your doctor. It is advisable that patients with glucose-6-phosphate dehydrogenase deficiency, chronic or recurrent gastric and intestinal disorders or impaired renal function be consulted with the physician. In the case of a sodium-free or low-sodium diet, it should be noted that each tablet of the product contains about 480 mg of sodium. The use of VIVIN C should be avoided concomitantly with NSAIDs, including selective COX-2 inhibitors. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal (see section 4.2). Gastrointestinal bleeding, ulceration and perforation: Gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported during treatment with all NSAIDs, at any time, with or without warning symptoms or a previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), the risk of gastrointestinal haemorrhage, ulceration or perforation is higher with increasing doses of NSAIDs. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low dose aspirin or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as aspirin (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking VIVIN C the treatment should be discontinued. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Caution should be exercised in patients with a history of hypertension and / or heart failure as fluid retention and edema have been reported in association with NSAID therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. VIVIN C should be discontinued at the first appearance of skin rash, mucosal lesions or any other signs of hypersensitivity.

Pregnancy and breastfeeding

- Low doses (up to 100 mg / day). Clinical studies indicate that doses up to 100 mg / day can be considered safe for use only in obstetrics, which requires specialist monitoring. - Doses of 100-500 mg / day. There are insufficient clinical data regarding the use of doses above 100 mg / day up to 500 mg / day. Therefore, the recommendations below for doses of 500 mg / day and above also apply to this dose range. - Doses of 500 mg / day and more. Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryo / fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor, in early pregnancy. The absolute risk of cardiac malformations was increased by less than 1% up to about 1.5%. The risk has been estimated to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause increased pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, acetylsalicylic acid should not be administered except in strictly necessary cases. If acetylsalicylic acid is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to: • cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension); • renal dysfunction, which may progress to renal insufficiency with oligo-hydroamnios. The mother and the newborn, at the end of pregnancy, to: • possible prolongation of the bleeding time and antiplatelet effect which may occur even at very low doses; • inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, acetylsalicylic acid at doses> 100 mg / day is contraindicated during the third trimester of pregnancy.

Expiration and retention

Do not store above 25 ° C. Keep the tube tightly closed to protect from moisture. For storage conditions after first opening see section 6.3.

Interactions with other drugs

Corticosteroids: increased risk of gastrointestinal ulceration or haemorrhage (see section 4.4). Anticoagulants: NSAIDs may enhance the effects of anticoagulants, such as warfarin (see section 4.4). Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal haemorrhage (see section 4.4). Administration of acetylsalicylic acid, especially in the case of prolonged therapy, can potentiate the undesirable effects of methotrexate, the effects and secondary manifestations of all non-steroidal antirheumatics, the effect of blood glucose-lowering drugs (sulfonylurea). Precaution should be observed for substances such as spironolactone, furosemide and antigout preparations, whose activity is instead reduced by acetylsalicylic acid. Therefore, unless otherwise prescribed, VIVIN C should not be administered concomitantly with the above preparations. Metamizole may reduce the effect of acetylsalicylic acid on platelet aggregation when taken simultaneously. Therefore, this combination should be used with caution in patients taking low-dose aspirin for cardioprotection


In case of overdose it is necessary to limit the absorption of the drug from the gastrointestinal tract (gastric lavage, activated carbon), to lower the body temperature (sponging with warm water), to compensate for dehydration with an adequate supply of fluids, to correct acidosis (bicarbonate of sodium iv) and possible hypoglycaemia. Even in the case of accidental intoxication by VIVIN C, the effervescent form presents a maximum degree of safety both for the reduction of the risk of massive administration and for the need to ingest large quantities of water.

Active principles

Each tablet contains: Active principles: acetylsalicylic acid 0.330 g, ascorbic acid 0.200 g. For the full list of excipients, see section 6.1


Glycine, anhydrous citric acid, sodium hydrogencarbonate, sodium benzoate.

11 Items